Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419 or 630-652-3042 internationally and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future development and therapeutic potential of quizartinib and Ambit's other drug candidates, progress and timing o
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... privately held full service global investment bank specializing ... an industry note featuring Spherix. The ... a Senior Analyst at Chardan, was published on ...
(Date:4/1/2015)... , April 1, 2015 ... developing novel biological drugs to treat cancer, viral ... announce the appointment of Christina Coughlin ... responsible for providing medical and regulatory leadership to ... Dr. Coughlin has extensive experience in ...
(Date:3/31/2015)... Materials in Society Lecture Series ... 30 2015   Elsevier , a world-leading ... and publishing home of Materials Today , announced that ... Materials in Society  Lecture Series . The ... International Conference on Materials for Advanced Technologies (ICMAT) ...
(Date:3/31/2015)... SALT LAKE CITY , March 31, 2015 /PRNewswire-USNewswire/ ... second milestone with the selection of ten proposals ... The MCRI is the first patient-led, scientifically validated ... patients. Stage 2 of the MCRI ... "After careful review of a large number of ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2
... Ltd.,(SWX: ARPN) today announced that Dr Jurgen Raths will ... Raths commands extensive,knowledge in the commercialisation of drugs for ... built and lead the European,Critical Care sales, medical and ... At the Annual General Meeting of 7 May, ...
... ,Exelixis, Inc. (Nasdaq: EXEL ) announced today that ... Exelixis, will present at the,Morgan Stanley Global Healthcare Unplugged ... 30, 2008. Dr. Scangos will discuss updates to,the company,s ... be webcast and may be accessed in the Event,Calendar ...
... Inc. (Nasdaq: IDIX ) announced today that ... upcoming Morgan Stanley Global,Healthcare Unplugged Conference on Wednesday, ... Ritz Carlton in Key Biscayne, Florida., The ... can be,accessed under "Calendar of Events" in the ...
Cached Biology Technology:Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 2Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 4
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... be the impact of the next green revolution on global ... climate change? To what extent can biofuels help make America ... be discussed at the International Annual Meetings of the American ... and Soil Science Society of America (SSSA), Oct. 31-Nov. 3 ...
... NY, October 28, 2010Mary Ann Liebert, Inc. announces the ... area of systems neuroscience, Brain Connectivity . This ... source of cutting-edge basic and clinical neuroscience research aimed ... the brain and how these connections are altered by ...
... by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at ... clinical laboratory for development and could soon result in a ... to determine when a lupus flare is imminent. ... way to predict when a person with systemic lupus is ...
Cached Biology News:Media alert: Agronomists, crop and soil scientists to convene in Long Beach 2New Brain Connectivity journal captures latest advances in neuroscience research 2New clinical test to predict lupus flares moves closer to the market 2
... (Intein Mediated Purification with an Affinity Chitin-binding ... engineered protein splicing elements (termed inteins) to ... column (1-4) (Figures 1 and 2). This ... systems by its ability to separate a ...
... Analysis Note: The kit contains all ... convenient determination of NADPH-cytochrome c reductase activity ... purified microsomes [endoplastic reticulum (ER)]. It has ... tissues such as liver, kidney, brain, spleen, ...
... provides the reagents to efficiently differentiate ... myotubes. By efficiently promoting myogenic differentiation, ... in studies examining myogenesis, transcription factor ... muscle cell replacement therapy. By providing ...
... CHEMICON's Cell Transformation Detection Assay is an ... is considered the most stringent assay for ... this assay, cells (pre-treated with carcinogens or ... in soft agar medium for 21-28 days. ...
Biology Products: